Influence of Obesity on Endogenous Oxalate Synthesis
Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Oct 9, 2018
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how obesity affects the body's production of oxalate, a substance that can lead to kidney stones. Researchers have found that people with obesity may produce more oxalate in their urine, which increases their risk of developing calcium oxalate stones. By putting participants on a controlled low oxalate diet, the study aims to compare how both obese and non-obese adults produce oxalate. The goal is to better understand the link between obesity and oxalate production, which could help in creating new ways to prevent kidney stones in the future.
If you are between 25 and 60 years old, with a body mass index (BMI) under 50, you might be eligible to participate in this study. However, people who have a history of kidney stones, diabetes, liver or kidney diseases, bowel diseases, or who are pregnant or planning to become pregnant cannot join. Participants will be asked to follow a specific diet and will help researchers gather important information that could lead to better prevention strategies for kidney stones. This research is currently recruiting, and everyone is welcome to apply, regardless of gender.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 25-60 years
- • Body Mass Index (BMI) \<50
- Exclusion Criteria:
- • history of kidney stones
- • history of diabetes, hepatic disease, renal disease including Chronic Kidney Disease (CKD), bowel disease or other endocrine disorders
- • pregnant or lactating women, or those with the intention to become pregnant in the near future
- • abnormal liver enzymes
- • hemoglobin A1C \> 6.5
About University Of Alabama At Birmingham
The University of Alabama at Birmingham (UAB) is a prominent academic institution and research hub dedicated to advancing healthcare through innovative clinical trials. Renowned for its commitment to medical discovery and education, UAB conducts cutting-edge research across a wide array of disciplines, including oncology, cardiology, neurology, and public health. With a robust infrastructure for clinical research, UAB fosters collaboration among interdisciplinary teams, leveraging state-of-the-art facilities and resources to enhance the translation of scientific findings into effective treatments and interventions. As a leader in clinical research, UAB aims to improve patient outcomes and contribute to the broader medical community through rigorous trial design and implementation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Patients applied
Trial Officials
Dean Assimos, MD
Principal Investigator
University of Alabama at Birmingham
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials